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Purpose. To evaluate prospectively the safety and efficacy of totally percutaneous placement of abdominal and thoracic
aortic endografts using the Prostar XL suture-mediated closure system.
Methods. From January 2002 to January 2005, we attempted to insert percutaneously all bifurcated abdominal aortic and
thoracic endografts. Consecutive patients (25 men, four women), with mean age 74.9 years (range 44e84), underwent
endovascular repair for 20 abdominal aortic aneurysms (AAA) and nine thoracic aortic aneurysms (repeat operation in
one case).
Endografts used included 21 Zenith (Cook), eight Talent (Medtronic), one AneuRx (Medtronic). For the «pre-close» tech-
nique, two Prostar XL 8F were used to close 22e24F access sites and one Prostar XL 10F to close 16F access sites.
Results. Procedural success was achieved in 21/29 (72.4%) patients and in 39/47 access sites (83%). Closure of 22e24F
access sites with tandem 8F Prostar devices was successful in 23/29 (79.3%) cases. Closure of 16F access sites with 10F
Prostar device was successful in 16/18 (88.8%) cases. There were seven peri-procedural failures requiring surgery to repair
the femoral artery in three cases. Four access complications healed without intervention. Overall 25/29 (86.2%) patients
had complete percutaneous repair. No late complications were detected during follow-up (median 17.5 months).
Conclusions. Percutaneous treatment of patients with AAA and thoracic aneurysms is feasible in most cases, with a very
low risk of access-related complication, providing that the operator has sufficient practical experience of this technique.
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Endovascular repair of abdominal aortic aneurysms
and thoracic aortic aneurysms have progressively
gained widespread acceptance. Devices currently
used are placed through relatively large sheaths
(16Fe26F), usually requiring open femoral artery cut-
down. This type of access, although limited, is associ-
ated with local groin complications such as infection,
haematoma, seroma in up to 14% of patients.1 Further-
more, open femoral artery exposure usually requires
general or spinal anaesthesia, produces patient dis-
comfort and prolongs hospital stay. Therefore, it has
been tempting to decrease the invasiveness of these
procedures by performing them percutaneously.
Haas et al.2 first described closure of 16F percutaneous
access sites using a suture-mediated closure device
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CA) which appeared, in comparison to other available
closure devices, able to seal access sites as large as 16F.
Later, some authors reported successful percutaneous
endovascular aneurysm repairs.3e6
The objective of this study was to assess prospec-
tively the feasibility, safety and efficacy of complete
percutaneous endograft deployment for AAA, as
well as for thoracic aneurysms.
Methods
Between January 02 and January 05, we attempted to
insert percutaneously all infrarenal aortic endografts
as well as thoracic endografts. Data were collected
prospectively including demographics, duplex ultra-
sound (US) scan of accessed femoral arteries and de-
vice failures. Device failure was recorded and we
analyzed the reasons for our access complications
with a product specialist from the devicemanufacturer.
All patients had a duplex US scan of accessed fem-
oral arteries prior to the procedure to determine the
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or posterior localization of a calcified plaque also
was recorded. During follow-up, the surveillance of
access sites was based on duplex US scan, post oper-
atively and at 3 months searching for any access
related complication as haematoma, arteriovenous
fistula, pseudoaneurysm, stenosis and occlusion.
Exclusion criteria were implantation of an aorto-
uni-iliac endograft, heavily scarred groin, presence
of an inguinal arterial prosthesis and severely calci-
fied femoral arteries with anterior calcifications
revealed by duplex ultrasound scan. This resulted in
the exclusion of eight patients due to seven cases of
aorto-uni-iliac endografts, combined with a femoro
femoral bypass and one case with previous aorto-
bi-femoral bypass graft, where femoral artery cut-
down was used to insert a thoracic aortic endograft.
The procedures were performed by the vascular sur-
gical team in the operating room under general anaes-
thesia. All percutaneous access with the Prostar XL
device according to the ‘pre-close’ technique7 was
performed by the same surgeon (JW).
Technique
The Prostar XL is a suture-mediated closure device
used to close femoral arterial access sites of 8e10F
sheaths. The device consists of two components:
a sheath that holds two pairs of needles connected
with a suture loop and a rotating barrel, used to accu-
rately position the device prior to needle deployment
and to guide the needles through the subcutaneous
tract. The 8F and 10F devices deliver two pairs of
needles and two sutures. The 8F and 10F Prostar XL
devices are used to close access sites after inter-
ventional procedures performed through 7Fe10F
sheaths. Larger sheaths require a different technique
(‘pre-close’ technique), where a percutaneous closure
device is deployed at the start of the procedure, before
the arteriotomy is enlarged by introduction of sheaths
larger than 10F. A 10F Prostar XL is used to close
access sites up to 16e18F. When sheaths over 16e
18F are used, two 8F Prostar are routinely used, the
second closure device (8F) being inserted in a similar
manner except that the needles are deployed at 45 de-
grees clockwise in relation to the first device. The ‘pre-
close’ technique has been described previously.2,5,7
Once the endograft is inserted and before removing
the sheath, sutures are generously soaked with hepa-
rin saline and tested to ensure that they run freely. The
sheath and the guide wire are then removed while
proximal pressure is maintained, and sutures are fas-
tened individually with a sliding knot. A knot pusherEur J Vasc Endovasc Surg Vol 32, September 2006is used to ensure approximation of the knot to the sur-
face of the vessel wall. Manual pressure is then re-
leased. Suture ends are cut well beneath the surface
of the skin. Incisions are closed with a single suture
or with adhesive steri strips. Concerning the guide
wire, it can be either removed before tying sutures,
or maintained in place. In cases where haemostasis
is not obtained, if the wire access has been main-
tained, a sheath can be readvanced over the wire to
control the haemorrhage and a femoral cutdown is
then performed. All patients received a single intra-
venous regimen of antibiotics at the beginning of the
procedure.
Postoperatively all patients underwent a physical
examination, a duplex ultrasound scan and determi-
nation of ankle-brachial index. Outpatient follow-up
was performed at 1, 6, 12 months and yearly thereafter.
The primary end point was access-related compli-
cations, including infection, bleeding, arterial stenosis,
occlusion and pseudoaneurysm. Procedural success
was defined as the completion of percutaneous place-
ment of the endograft, without any complication at
the access sites.
Data are expressed as mean SEM. The chi-square
test or Fisher exact test was used to compare nominal
variables. Statistical significance was assumed at
p< .05.
Results
Twenty-nine consecutive patients 25 men, four
women, mean age: 74.9 years (range: 44e84) who
underwent endovascular repair of an AAA (20) and
thoracic aortic aneurysms9 were assessed for evidence of
access related complications. One woman with a tho-
racic aortic aneurysm had a secondary endovascular
procedure at 7 months for a distal type I endoleak.
The additional endograft was inserted percutaneously
via the same femoral artery previously accessed. The
number of patients recruited during this period of
time was curtailed by the strict limitations imposed in
France by health authorities since October 2001,
restricting indications for endovascular treatment of
AAA to high-risk patients. Thus, in this study, all pa-
tients with AAAwere classified as high risk according
to the AFSSAPS classification (Agence Franc¸aise pour
la Se´curite´ Sanitaire des Produits de Sante´). The 29 pa-
tients described in this report represented approxi-
mately one tenth of patients operated on for AAA in
our unit. Therewere 18 bifurcated abdominal aortic en-
dografts, two abdominal aortic tubes and 10 thoracic
aortic endografts. In one patient (with bifurcated
endograft), a heavily calcified femoral artery on the
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artery cutdown on one side.
Endografts used were: Zenith (Cook): 21 (abdomi-
nal: 15, thoracic: six), Talent (Medtronic): eight (ab-
dominal: four, thoracic: four), AneuRx (Medtronic):
one (abdominal). Inner and outer diameters were,
respectively, 20/23 F for Zenith abdominal and 22/25
for Zenith thoracic. Outer diameters were 18/21 F
for AneuRx abdominal, 18/24 F for Talent abdominal
and 20/25 F for Talent thoracic. Twenty-nine patients
had 47 percutaneous closure and one femoral artery
cutdown. We used 58 Prostar XL 8F (two 8F to close
22e24F access sites) and 18 Prostar XL 10F (to close
16F access sites).
Procedural success was achieved in 21 (72.4%)
patients and at 39 (83%) access sites. Twenty-nine at-
tempts at percutaneous closure of 22e24F arteriotomy
with tandem 8F Prostar devices resulted in 23/29
(79.3%) successes. Eighteen attempted percutaneous
closures of 16F arteriotomy with 10F Prostar device
resulted in 16/18 (88.8%) successes.
There were seven periprocedural failures in seven
patients which, respectively, occurred on the 3, 5, 7,
8, 11, 14, 19th cases. Reasons for failures were identi-
fied in four cases: difficult device introduction due
to iliac tortuosity in one case, femoral calcifications
underestimated by the duplex scan in one case and
missing sutures in two cases. In one case, a needle
was deflected through the skin by a calcified plaque.
These failures resulted in three per-operative surgical
exposures of the accessed artery for surgical repair,
one pseudoaneurysm which occurred at day 3 and
spontaneously healed, three bleeds which spontane-
ously healed following prolonged compression and
one minor bleed occurred at day 2 requiring addi-
tional compression. One delayed bleed occurred at
day 9 and was treated by a surgical intervention to
repair the femoral artery.
Despite an access complication in four cases (one
pseudoaneurysm and three bleeds which healed with-
out surgical conversion), complete percutaneous
repair was achieved. Thus, overall 25/29 (86.2%)
patients had an entirely percutaneous repair.
No late complication was detected during the
follow-up, median 17.5 months (IQR 9e26 months).
Discussion
The results of this prospective series are satisfactory
and confirm the feasibility, safety and efficacy of percu-
taneous repair of aortic aneurysms. The percutaneous
deployment of both abdominal aortic and thoracic en-
dografts was successful in 72.4% of patients (21/29)with no complications. Of the seven periprocedural
access complications, four resolved spontaneously
allowing a complete percutaneous repair in 86.2% of
patients. Percutaneous closure of the main access site
(22e24F) was successful in 79.3% of patients, while
closure of the 16F access site was successful in 88.8%.
(chi-square test: p¼ 0.25, Fischer’s exact test: p¼ 0.43).
Arterial closure devices, such as plug mediated
systems, originally were developed for use with small
access sheaths and work relatively well up to 8F
sheath, however, they cannot be used safely to close
arterial punctures with 10F or larger sheaths. The
suture-mediated Prostar XL device (8e10F) can be
used «off-label» to percutaneously close large access
sites up to 24 or 26F, required to place abdominal aor-
tic endografts as well as thoracic endografts.1,2,4e7 The
advantages are obvious: allowing placement of aortic
endografts while avoiding femoral artery cutdowns,
thus decreasing the invasiveness of these procedures.
The percutaneous procedure also maintains, at least
partially, perfusion of lower limbs. Aortic endograft-
ing can, therefore, be performed in high risk patients
under regional or even local anaesthesia.
However, the ‘off-label’ use of this device is not free
of risk and complications and requires special exper-
tise.7 Clearly, there is a learning curve associated with
the use of suture-mediated closure devices: in our
series, most complications were due to technical prob-
lems, which occurredmainly at the beginning of the se-
ries. These complications could have been prevented
by more experience with the Prostar device. All com-
plications except two (delayed bleeding at day 9 and
pseudoaneurysm at day 3) occurred during the proce-
dure itself, requiring immediate treatment with surgi-
cal exposure of the accessed artery in three cases.
Despite the deleterious effect of the learning curve,
our results compare favourably with those reported in
the literature. Table 1 summarizes literature rates of
successful percutaneous endograft insertions without
conversion to an open groin incision. Success rates
vary from 46.26 to 93%.3 These results differ from suc-
cess rates of unilateral percutaneous femoral artery
closure as demonstrated in the series of Traul et al.
where success rates in percutaneous deployment of
Table 1. Success rates of percutaneous endograft insertions
Author Procedures (n) Success rate (%)
Morasch7 47 85.1
Torsello8 15 86.6
Teh5 42 73.8
Rachel4 44 63
Traul6 12 46.2
Howell3 30 93
Personal series 30 86.2Eur J Vasc Endovasc Surg Vol 32, September 2006
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the contralateral limb via a 16F sheath were, respec-
tively 61.5 and 64.7%, whereas the rate of complete
percutaneous endograft repair was only 46.2%.6 Re-
sults also vary with sheath size (Table 2). It is postu-
lated that results of percutaneous closure of 16F
access sites are better than those of larger access sites
(22e25F) required to implant abdominal and thoracic
aortic endografts. In the study of Rachel et al., intro-
ducer sheath size was the only predictor of successful
percutaneous closure based on multivariate analysis.4
In our series, perhaps due to the small number of
patients, the difference in the rate of success between
closure of 16F and larger access sites (22e25F) was not
statistically significant. We suggest that observed dif-
ferences in the literature might reflect the learning
curve of a technique, which is slightly more difficult
to master using two Prostar devices instead of one.
We observed no cases of infection in our small se-
ries. Although the reported incidence of infection after
placement of percutaneous suture-mediated devices is
low (reported as 0.2% by Johanning et al.8), conse-
quences of this complication may be potentially devas-
tating. Prevention is best ensured by pre-procedural
antibiotics, together with a sterile technique (sterile
adhesive draping, etc.) and environment, optimally
offered in the operating room.
Some technical points deserve discussion. For
sheaths over 18F, most teams use tandem devices (8F
or 10F), the second device being rotated 45  clockwise
according to themanufacturer’s recommendations.5 In
contrast, Howell et al. recommended rotation of the
second Prostar device by 90  instead of 45 , arguing
that ‘this rotation prevents the sutures of each device
from being placed in the same location in the arterial
wall’.3 However, by doing this the chances are that su-
tures of each device would have the exact same loca-
tion in the arterial wall, thus potentially making the
edges of the arteriotomy more fragile. Instead of using
tandem devices, Torsello et al. used only one Prostar
10F for closure of all access sites, regardless of sheath
size.9 These authors suggested that ‘too many threads
can cause catching on other sutures, disrupting the
vessel wall during fastening of the knot’. This risk is
minimal if a rigorous technique is observed with
Table 2. Success rates of percutaneous femoral artery closure
according to sheath size
Author Procedures (n) Success rate (%) Sheath size (F)
Traul6 12 16 22
Rachel4 44 64.7 61.5
Howell1 144 85 64
Howell3 30 94.4 96
Personal series 30 88.8 79.3Eur J Vasc Endovasc Surg Vol 32, September 2006sutures placed carefully and maintained in radial ori-
entation. All loops of sutures should be kept taut
and generously soaked with heparin saline, ensuring
that sutures run freely by alternatively pulling on
both ends gently and then tied in order of placement.
Moreover, we observed that although haemostasis
usually was obtained after tying the second knot, in
some cases, the third and sometimes the fourth knot
were necessary to achieve hemostasis, avoiding the
need for additional compression.
To avoid that sutures may cut through the arterial
wall when the 10F arteriotomy is later on dilated to
20F or more, similarly to Howell et al.,3 we dilated
both the arteriotomy and iliac arteries with dilators of
progressive size before inserting the endograft. This
technique also has the advantage of facilitating the ad-
vancement of the endograft via iliac arteries. Major tor-
tuosity may prevent the progression of the device and
it accounted for one failure in our series. This problem
can be overcome by using a rigid or a semi-rigid guide
wire that facilitates the progression of the device by
correcting the tortuosity. Inguinal scarring, presence
of a femoral arterial prosthesis and calcifications can
prevent the needles from being retrieved or can cause
the deflection of a needle. In these situations, the oper-
ator can attempt to push back the needles into the hub
by pushing the handle back into the device. Fluoros-
copy can help to determine the position of the needles:
if they are successfully returned to the hub, the Prostar
device can be removed and replacedwith a newone.1 If
this manoeuvre does not correct the problem, or if
a needle deflected in subcutaneous tissue and cannot
be retrieved, conversion to an open groin incision is
necessary to remove the needles and repair the femoral
artery. According to Traul et al., the wiremay be kept in
place until the sutures are tied and the haemostasis
achieved.6 In case of unsuccessful percutaneous clo-
sure, the wire maintained in place allows to reinsert
a sheath to control the bleeding during the surgical
exposure. However, leaving the wire in place could
expose to tying the sutures on the wire as reported by
Howell et al. in two cases.3 The use of a hydrophilic
wire could minimise this risk.
There are several contraindications to percutaneous
closure technique. First is a severely calcified femoral
artery shown on duplex ultrasound scanning, espe-
cially if calcifications are anterior. However, in the pro-
spective randomized study performed by Starnes et al.,
percutaneous closures were successfully achieved in
arteries with anterior calcification.10 Second is
a heavily scarred groin or the presence of an inguinal
arterial prosthesis.10 Third, morbid obesity is often
cited as a cause of failure.5,6,9 Although percutaneous
treatment may be more difficult in obese patients, it
265Percutaneous Repair of Aortic Aneurysmsis highly beneficial in this context when successful,
avoiding the risks of an open arterial access.7
Conclusion
Percutaneous treatment of patients with AAA is
almost always feasible with a very low risk of
access-related complications. We recommend that
percutaneous treatment of AAA be performed by ex-
perienced endovascular specialists who are familiar
with the Prostar device. The procedure should be
performed in an operating room, in cases where con-
version to an open groin exposure is required.
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